Martin H. Voss, MD, provides an overview of advanced non–clear cell renal cell carcinoma (nccRCC), highlighting epidemiology and pathological classification.
Video content above is prompted by the following question(s):
Please provide an overview of advanced non-clear cell renal carcinoma (nccRCC), including its epidemiology, typical disease presentation, and risk stratification factors.
LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.